Authors



Joshua Fitch

Latest:

RSV Prophylaxis: Palivizumab, Nirsevimab, and More

Current prevention strategies include two injectables for infants and young children, namely palivizumab and nirsevimab.


Christina Lee, PharmD

Latest:

Immunocompromised Patients on OPAT Face Nearly Double the Risk of 30-Day Readmission

Christina Lee, PharmD, and Julia Donahue, PharmD, analyzed 533 encounters revealing a 27.1% readmission rate in immunocompromised patients versus 14.1% in non-immunocompromised patients.


Tipu V. Khan, MD

Latest:

The Future and Resources in HCV Care

Expert hepatologists discuss future developments in HCV that they are excited about and provide resources for new providers to get started on delivering HCV care.


Kellie Hawkins, MD

Latest:

HIV and Long COVID Insights from the RECOVER Program on Risk and Diagnosis

Kellie Hawkins, MD discusses the findings along with the challenges of diagnosing Long COVID in people with HIV, emphasizing the need for improved clinical recognition and education.


Brian Ubhaus, PharmD

Latest:

A Case of Candida Albicans Ventriculitis Secondary to E Coli Ventriculoperitoneal Shunt Infection

Rare cases of health care–associated meningitis and ventriculitis in adults caused by Candida species are associated with recent bacterial meningitis and broad-spectrum antibiotic use.


Christian Marsolais, PhD

Latest:

FDA Approves F8 Formulation of Theratechnologies' Tesamorelin for HIV-Associated Lipodystrophy

Theratechnologies' new tesamorelin formulation provides a simplified, long-acting dosing regimen to effectively manage excess abdominal fat in adults with HIV-associated lipodystrophy.


Marice Ruiz Conejo Castillo, MD

Latest:

Challenges in the Management of Mycobacterium abscessus Complex

This pathogen is the third most frequently isolated nontuberculous mycobacteria seen in the United States. Here is a review of how it presents and treatment options.


Andrés Finzi, PhD

Latest:

Targeting Soluble gp120 to Combat Immune Dysfunction in People Living with HIV

At CROI 2025, researchers from Université de Montréal discuss how fostemsavir could target residual viral fragments and reduce inflammation.



Renslow Sherer, MD

Latest:

Lessons in Resilience: What HIV Teaches Us About COVID-19

Four lessons learned from the AIDS crisis that can be applied to the fight against our current pandemic.


Bincy Abraham, MD, MS

Latest:

Advice for Physicians to Manage C. Difficile Infection (CDI)

Experts share advice for physicians taking care of patients with C. difficile infection (CDI).


Walaiporn Wangchinda, MD

Latest:

Sulbactam for Treatment of Carbapenem-Resistant Acinetobacter baumannii

This is a challenging pathogen, requiring pharmacokinetic and pharmacodynamic considerations; the recent FDA approval of sulbactam-durlobactam offers new hope.


Maureen Hennessey, PHD, CPCC, CPHQ

Latest:

The Tripledemic as a Precursor to Stakeholder Alignment under the Quintuple Aim

Infectious disease outbreaks will continue to increase and trying to find strategies to ensure providers are cared for to prevent burnout and shortage staffing is essential if another pandemic arises.



Marc H. Scheetz, PharmD, MSc

Latest:

Precision in Practice: PK/PD Modeling Advances Infectious Disease Care

At MAD-ID, Marc Scheetz, PharmD, discusses how PK/PD modeling and AUC-based strategies offer safer, more precise antibiotic therapy.


Maryann Webb

Latest:

Advocating for Better Regulatory Rules and Standard of Care for C difficile

Maryann Webb’s harrowing, personal experience with C diff, along with her professional work with federal agencies has prepared her for a life in advocacy with the Peggy Lillis Foundation. She wants to see the fecal microbiota transplant become more accessible and is working with Congress to make the infection a notifiable infectious disease.


Sara Rendell, PHD

Latest:

Community-Acquired Candida Glabrata Empyema: An Atypical Diagnosis Not to Miss

Although this patient had none of these common risk factors associated with Candida empyema, she did have other factors predisposing her to fungal colonization and subsequent infection.


Ellora Karmarkar, MD, MSc

Latest:

Candida auris: Coming Soon to a Facility Near You?

Epidemiologic and clinical lessons for the uninitiated.


Teena Chopra, MD, MPH

Latest:

Tips for Talking with Patients about Fecal Microbiota Transplant for Recurrent C. difficile Infections

To close the discussion, experts on C. difficile infections discuss how they talk with patients about fecal microbiota transplantation.


Nikita Jaggernauth, MD

Latest:

Tuberculosis Meningitis in an Immunocompetent Patient

Read more about the case of a 71-year-old man who was admitted after presenting with cold-like symptoms for 3 weeks.


Carole Mitnick, ScD

Latest:

endTB Trial Paves Way for Shorter, Cheaper, and Safer Rifampin-Resistant TB Treatments

Carole Mitnick, ScD discusses the impact of the endTB trial's findings on future TB treatment options, including shorter treatment durations, lower costs, and expanded accessibility.


Bill Hathaway

Latest:

How Typhoid Fever Triggers Severe Neurological Symptoms

Yale researchers have discovered how typhoid fever triggers neurological symptoms, offering new insight into treatment options.


Sunish Shah, PharmD, BCIDP

Latest:

An Overview of Cefiderocol Resistance Among Clinical Pathogens

Here is a review the mechanisms that lead to resistance, including risk factors.



Michael McAlister, PharmD, BCIDP

Latest:

STAY PrEPARED: Understanding COVID-19 Pre-Exposure Prophylaxis

New therapeutics offer some hope in this emerging market.


Jennifer Ronholm, PhD

Latest:

Agriculture and Antibiotics: Trying to Protect the Former and Preserve the Latter

Jennifer Ronholm, PhD, discusses the novel concept of microbiome protection to create healthier animals and reduce antimicrobial usage.



Rebecca Leach, MPH, BSN, RN, CIC

Latest:

Health Equity and the Impact on Infectious Disease

Inequities can include access to care issues that run from prevention to acute treatment. Addressing such issues can lead to better outcomes.


James A. McKinnell, MD

Latest:

Looking Toward the Future of CDI Management

Closing out their discussion on Clostridioides difficile infection, panelists share closing thoughts on novel pipeline therapies.

© 2025 MJH Life Sciences

All rights reserved.